Edition:
United Kingdom

Basilea Pharmaceutica AG (BSLN.S)

BSLN.S on Swiss Exchange

51.65CHF
19 Sep 2018
Change (% chg)

CHF-2.65 (-4.88%)
Prev Close
CHF54.30
Open
CHF54.00
Day's High
CHF54.05
Day's Low
CHF51.10
Volume
250,027
Avg. Vol
60,024
52-wk High
CHF84.10
52-wk Low
CHF51.10

Chart for

About

Basilea Pharmaceutica AG is a Switzerland-based company engaged in the research, development and commercialization of pharmaceutical products. The Company focuses on pharmaceutical products in the therapeutic areas of bacterial infections, fungal infections and oncology. The Company has a range of drugs to treat drug-resistant... (more)

Overall

Beta: 1.31
Market Cap(Mil.): CHF947.87
Shares Outstanding(Mil.): 11.86
Dividend: --
Yield (%): --

Financials

  BSLN.S Industry Sector
P/E (TTM): -- 85.68 32.76
EPS (TTM): -4.21 -- --
ROI: -17.70 1.78 14.61
ROE: -- 3.29 16.33

BRIEF-Basilea Pharmaceutica Sees 2018 Oper Loss At CHF 25-35 Mln

* H1 OPERATING LOSS OF CHF 20.4 MILLION COMPARED TO CHF 19.1 MILLION IN H1 2017

14 Aug 2018

BRIEF-Basilea Pharmaceutica: Approval For Antifungal Cresemba (Isavuconazole) In Jordan

* HIKMA PHARMACEUTICALS LLC, GAINED REGULATORY APPROVAL FOR ANTIFUNGAL CRESEMBA (ISAVUCONAZOLE) IN JORDAN Source text for Eikon: Further company coverage: (Gdynia Newsroom)

13 Aug 2018

BRIEF-Basilea Starts Clinical Phase 3 Study With Antibiotic Ceftobiprole In Staphylococcus Aureus Bacteremia

* BASILEA STARTS CLINICAL PHASE 3 STUDY WITH ANTIBIOTIC CEFTOBIPROLE IN STAPHYLOCOCCUS AUREUS BACTEREMIA (SAB) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

09 Aug 2018

BRIEF-Basilea Pharmaceutica Reports Receipt Of Payment Based On First Cresemba Approval In Latin America

* REPORTS RECEIPT OF MILESTONE PAYMENT BASED ON FIRST CRESEMBA® APPROVAL IN LATIN AMERICA

19 Jul 2018

BRIEF-Basilea Pharmaceutica Starts Clinical Phase 2A Expansion With Bal101553 In Ovarian Cancer And Glioblastoma

* STARTS CLINICAL PHASE 2A EXPANSION WITH BAL101553 IN OVARIAN CANCER AND GLIOBLASTOMA Source text for Eikon: Further company coverage: (Gdynia Newsroom)

26 Jun 2018

BRIEF-Basilea Pharmaceutica Appoints Gerrit Hauck As CTO

* GERRIT HAUCK APPOINTED AS CHIEF TECHNOLOGY OFFICER Source text for Eikon: Further company coverage: (Gdynia Newsroom)

27 Apr 2018

BRIEF-Basilea: Start Of Clinical Phase 3 Study In Japan

* BASILEA REPORTS START OF CLINICAL PHASE 3 STUDY IN JAPAN BY ASAHI KASEI PHARMA WITH ANTIFUNGAL ISAVUCONAZOLE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

18 Apr 2018

BRIEF-Arqule And Basilea Enter Into Exclusive License Agreement For Derazantinib

* ARQULE AND BASILEA ENTER INTO EXCLUSIVE LICENSE AGREEMENT FOR DERAZANTINIB IN THE US, EU, JAPAN AND REST OF WORLD EXCLUDING GREATER CHINA

17 Apr 2018

BRIEF-Basilea Pharmaceutica Licenses Late-Stage Oncology Drug Candidate Derazantinib

* LICENSES LATE-STAGE ONCOLOGY DRUG CANDIDATE DERAZANTINIB FROM ARQULE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

17 Apr 2018

BRIEF-Basilea Pharmaceutica: Partner Avir Pharma Launches Basilea's Ceftobiprole In Canada

* ITS PARTNER AVIR PHARMA INC HAS LAUNCHED BASILEA'S HOSPITAL ANTIBIOTIC ZEVTERA (CEFTOBIPROLE) IN CANADA Source text for Eikon: Further company coverage: (Gdynia Newsroom)

09 Apr 2018

Earnings vs. Estimates